Evidence map›Paper›PMID 41641665›Full record

ReviewAllergy2026

Updated Treatment of Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report.

Gülfem E Çelik, Joanna S Makowska, Maria Jose Torres, Cristobalina Mayorga, Tanya M Laidlaw, Alessandra Vultaggio, Sanna Toppila-Salmi, Ludger Klimek, Aslı Gelincik, Annick Barbaud and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gülfem E ÇelikDepartment of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine, and Private Practice, Ankara, Türkiye.ORCID https://orcid.org/0000-0001-8654-513X
Joanna S MakowskaDepartment of Rheumatology and Clinical Immunology, Medical University of Lodz, Lodz, Poland.ORCID https://orcid.org/0000-0003-2036-375X
Maria Jose TorresAllergy Research Group, IBIMA Plataforma BIONAND, Málaga, Spain.ORCID https://orcid.org/0000-0001-5228-471X
Cristobalina MayorgaAllergy Unit, Hospital Regional Universitario de Málaga and IBIMA Plataforma BIONAND, Málaga, Spain.ORCID https://orcid.org/0000-0001-8852-8077
Tanya M LaidlawDivision of Allergy and Clinical Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6709-9795
Alessandra VultaggioDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Sanna Toppila-SalmiDepartment of Otorhinolaryngology, Wellbeing Service County of Pohjois-Savo, Kuopio, Finland.ORCID https://orcid.org/0000-0003-0890-6686
Ludger KlimekCenter for Rhinology and Allergology, Wiesbaden, Germany.ORCID https://orcid.org/0000-0002-2455-0192
Aslı GelincikDivision of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.ORCID https://orcid.org/0000-0002-3524-9952
Annick BarbaudService de Dermatologie et d'Allergologie, Hôpital Tenon, Paris HUEP, APHP, Sorbonne Université, Paris, France.ORCID https://orcid.org/0000-0001-8889-1589
Lene H GarveyAllergy Clinic, Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-7777-4501
Ömür AydınDepartment of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Türkiye.ORCID https://orcid.org/0000-0002-3670-1728
Thomas EiweggerDepartment of Clinical Immunology, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.ORCID https://orcid.org/0000-0002-2914-7829
Katharine M WoessnerDivision of Allergy, Asthma and Immunology, Scripps Clinic Medical Group, San Diego, California, USA.ORCID https://orcid.org/0000-0001-7213-8760

Funding

European Academy of Allergy and Clinical Immunology 40333
6 · The paper itself

Abstract

Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NSAID-ERD) is a heterogeneous condition characterized by chronic eosinophilic airway inflammation in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma whose symptoms are aggravated after ingestion of aspirin and other NSAIDs. As a unique treatment, aspirin treatment after desensitization (ATAD) has been in use for several years after showing the inhibitory effect on CRS symptoms and nasal polyp growth as well as severe asthma. However, in recent years, biologics have also shown to cause a decrease in polyp size as well as associated outcomes such as quality of life. In this manuscript, considerations on choosing the best treatment of NSAID-ERD are laid out based on current literature.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalAspirinAsthma, Aspirin-InducedBiological ProductsDesensitization, ImmunologicRespiratory Tract DiseasesHumansNasal PolypsRhinosinusitisTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalAspirinBiological Productsaspirin desensitizationaspirin exacerbated respiratory diseaseaspirin treatment after desensitizationasthmabiologicschronic rhinosinusitis with nasal polyps (CRSwNP)endoscopic sinus surgeryNSAIDs exacerbated respiratory disease

Identifiers

PMID41641665
PMCPMC13466261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.